Diabetes

The latest diabetes and endocrinology news from UNC Health Care and the UNC School of Medicine.

Common diabetes drug not linked to short-term risk of pancreatic cancer

Common diabetes drug not linked to short-term risk of pancreatic cancer

UNC researchers overturn a controversial study about DPP-4 inhibitors – commonly prescribed diabetes medications.

Common diabetes drug not linked to short-term risk of pancreatic cancer - Read More…

Join our #T1Dchat on Twitter – Aug. 19 at 1 p.m. ET!

Join our #T1Dchat on Twitter – Aug. 19 at 1 p.m. ET!

Participating in the chat will be two diabetes experts and co-authors of a new American Diabetes Association position statement on the care of people with type 1 diabetes.

Join our #T1Dchat on Twitter – Aug. 19 at 1 p.m. ET! - Read More…

MUSC and UNC-Chapel Hill join forces to test a diabetes outreach program

MUSC and UNC-Chapel Hill join forces to test a diabetes outreach program

The Bamberg Diabetes Transitional Care Study will utilize cutting-edge iPad technology to explore the impact and feasibility of different diabetes interventions for patients transitioning from the hospital to home.

MUSC and UNC-Chapel Hill join forces to test a diabetes outreach program - Read More…

Buse recognized as leading expert in type 2 diabetes

Buse recognized as leading expert in type 2 diabetes

John B. Buse, MD, PhD, chief of the division of endocrinology and director of the Diabetes Care Center, has been ranked as one of the world’s foremost experts in type 2 diabetes based on an analysis of publications in the National Library of Medicine’s MEDLINE database.

Buse recognized as leading expert in type 2 diabetes - Read More…

UNC and SAS join forces to personalize health care for better outcomes

Collaboration will leverage big data to help providers engage patients to manage diabetes, improve health

UNC and SAS join forces to personalize health care for better outcomes - Read More…

UNC begins clinical trial of EndoBarrier® for treatment of type 2 diabetes

UNC begins clinical trial of EndoBarrier® for treatment of type 2 diabetes

The ENDO Trial is currently enrolling adults between the ages of 21 and 65 who have uncontrolled type 2 diabetes and are obese.

UNC begins clinical trial of EndoBarrier® for treatment of type 2 diabetes - Read More…

UNC Diabetes Care Center begins recruitment for long-term study of diabetes drug efficacy

UNC Diabetes Care Center begins recruitment for long-term study of diabetes drug efficacy

Beginning recruitment in June, the project is called the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study. UNC will enroll patients at locations in Durham and Greensboro, N.C.

UNC Diabetes Care Center begins recruitment for long-term study of diabetes drug efficacy - Read More…

To test or not to test:  Blood glucose monitoring for patients with type 2 diabetes

To test or not to test: Blood glucose monitoring for patients with type 2 diabetes

The Patient-Centered Outcomes Research Institute awards UNC School of Medicine researchers more than $2 million to study glucose monitoring in non-insulin treated patients living with type 2 diabetes.

To test or not to test: Blood glucose monitoring for patients with type 2 diabetes - Read More…

Diabetes investigation in rats makes editor's pick in APS journal

An investigation into diabetes-related outcomes in a rat model, with senior author William Valdar, PhD, assistant professor of genetics at UNC, and first author Leah Solberg Woods, PhD, from the Medical College of Wisconsin, has made the editor's pick in this month's Physiological Genomics, a journal of the American Physiological Society.

Diabetes investigation in rats makes editor's pick in APS journal - Read More…

UNC's Dr. John Buse named to international diabetes prize selection jury

UNC's Dr. John Buse named to international diabetes prize selection jury

The 2013 Harold Hamm International Prize for Biomedical Research in Diabetes encourages research focused on progress toward a cure.

UNC's Dr. John Buse named to international diabetes prize selection jury - Read More…

Head-to-head trial of two diabetes drugs yields mixed results

Head-to-head trial of two diabetes drugs yields mixed results

Daily injections of liraglutide were slightly more effective than weekly injections of exenatide in lowering blood sugar and promoting weight loss. However, patients had fewer negative side effects on exenatide once weekly.

Head-to-head trial of two diabetes drugs yields mixed results - Read More…

Three UNC specialties nationally ranked by U.S. News

Three UNC specialties nationally ranked by U.S. News

Overall, eleven specialties at UNC Hospitals were recognized as nationally ranked or high performing by U.S. News & World Report in its annual "America's Best Hospitals" issue.

Three UNC specialties nationally ranked by U.S. News - Read More…

Antibodies reverse Type 1 diabetes in new immunotherapy study

Antibodies reverse Type 1 diabetes in new immunotherapy study

Scientists at the University of North Carolina School of Medicine have used injections of antibodies to rapidly reverse the onset of Type I diabetes in mice genetically bred to develop the disease.

Antibodies reverse Type 1 diabetes in new immunotherapy study - Read More…

Join Dr. John Buse for live Facebook chat on diabetes

Join Dr. John Buse for live Facebook chat on diabetes

Dr. John Buse, director of the UNC Diabetes Care Center and chair of the National Diabetes Education Program, will host a live Facebook chat on diabetes management and prevention on Tuesday, May 22.

Join Dr. John Buse for live Facebook chat on diabetes - Read More…

Scientists awarded $2.4 million to study genetic variation in people with diabetes

Scientists awarded $2.4 million to study genetic variation in people with diabetes

The goal of the study is to identify genetic variations that may help predict the response to various treatment options for type 2 diabetes to reduce cardiovascular disease.

Scientists awarded $2.4 million to study genetic variation in people with diabetes - Read More…

First clinic to receive NCQA Diabetes Recognition Program recertification via new electronic submission

The UNC Internal Medicine Clinic achieved recertification for the National Committee for Quality Assurance (NCQA) Diabetes Recognition Program November 2011-2014.

First clinic to receive NCQA Diabetes Recognition Program recertification via new electronic submission - Read More…

UNC study helps clarify link between high saturated fat diet and type 2 diabetes

UNC study helps clarify link between high saturated fat diet and type 2 diabetes

New research from the University of North Carolina at Chapel Hill School of Medicine adds clarity to the connection. The study published on-line April 10th in the journal Nature Immunology finds that saturated fatty acids but not the unsaturated type can activate immune cells to produce an inflammatory protein, called interleukin-1beta.

UNC study helps clarify link between high saturated fat diet and type 2 diabetes - Read More…

UNC expert: Combining exenatide with insulin may be 'best result ever' for diabetes patients

UNC expert: Combining exenatide with insulin may be 'best result ever' for diabetes patients

A new study finds that combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients with type 2 diabetes than insulin alone and helps promote weight loss.

UNC expert: Combining exenatide with insulin may be 'best result ever' for diabetes patients - Read More…

Blog: One physician's take on the Avandia controversy...

Blog: One physician's take on the Avandia controversy...

When asked his thoughts about the Avandia controversy, Dr. John Buse, director of the UNC Diabetes Care Center and past president of the American Diabetes Association, had this to say…

Blog: One physician's take on the Avandia controversy... - Read More…

Share This: